News | Stents Drug Eluting | February 19, 2018

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

Recently approved by FDA, the EluNIR drug-eluting stent opens clogged arteries to restore blood flow in tortuous anatomy of patients with coronary artery disease

 

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent

February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently became the first in Michigan to offer patients with coronary artery disease a new treatment option for vessels that are difficult to stent because of the size and intricacy.

Tamam Mohamad, M.D., chief of cardiology at DMC Detroit Receiving Hospital, treated 60-year-old Haila Alamri, the mother of nine children and an armful of grandchildren, who was experiencing angina, with pressure in her chest, after walking short distances. The symptoms caused her a lot of fear and anxiety and greatly affected her quality of life.

Mohamad completed the procedure guiding the newly U.S. Food and Drug Administration (FDA)-approved EluNIR stent through a complex, circuitous course of blood vessels to reach and open a main artery that was 90 percent blocked. The three-hour procedure brought the blockage to 0 percent, and Friday, Haila Alamri went home the next day.

The EluNIR drug-eluting stent has the narrowest strut width of any FDA-approved stent currently available in the U.S. This low-profile stent, with radiopaque spring tip, makes it easier to maneuver in heavily calcified or intricately curved blood vessels.

“At the DMC, we strive to provide our patients with the newest treatment options to best serve their cardiac needs,” said Mohamad. “It’s the same kind of care I would provide for my own family.”

Mahir Elder, M.D., director of endovascular medicine at the DMC Heart Hospital, added, “The DMC Cardiovascular team's goal is to stay on the forefront of technology. As leading physicians in the field, we strive to bring the latest and greatest technology and innovation to the metro Detroit community.”

Cardiovascular disease is the No. 1 killer in the United States. According to the American Heart Association, each day about 2,200 Americans die from cardiovascular disease, about one person every 40 seconds.

During Heart Month, the DMC Cardiovascular team recommends patients seek medical attention immediately if they are experiencing any of the following common symptoms of a heart attack:

  • Severe pressure, fullness, squeezing, pain or discomfort in the center of the chest that lasts for more than a few minutes;
  • Pain or discomfort that spreads to the shoulders, neck, arms or jaw;
  • Chest pain that gets worse;
  • Chest pain that does not get better with rest or by taking nitroglycerin;
  • Chest pain that happens along with any of these symptoms:
    • Sweating, cool, clammy skin, or paleness
    • Shortness of breath
    • Nausea or vomiting
    • Dizziness or fainting
    • Unexplained weakness or fatigue
    • Rapid or irregular pulse

Although chest pain is the key warning sign of a heart attack, it may be confused with other conditions. These include indigestion, pleurisy, pneumonia, tenderness of the cartilage that attaches the front of the ribs to the breastbone, and heartburn.

For more information: www.dmc.org

Related Content

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Detroit Cardiogenic Shock Initiative Goes National at TCT 2017

DMC Heart Hospital Completes Complex High-Risk Indicated Interventional Procedure Course

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Overlay Init